Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Last Posted: May 24, 2024
spot light Spotlight

The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
(Posted May 24, 2024 9AM)

From the abstract: "A total of 190 papers were identified, 18 of which were eligible for inclusion. A cancer risk-assessment tool incorporating PGS was acceptable to the general practice population and their healthcare providers but major challenges to implementation were identified, including lack of evidence for PGS in non-European ancestry and a need for healthcare provider education in genomic medicine. A PGS cancer risk-assessment had relatively limited impact on psychosocial outcomes and health behaviours. However, for prostate cancer, potential applications for its use in primary care were shown. "

Turning the tide of early cancer detection
(Posted May 22, 2024 2PM)

From the abstract: "Next-generation liquid biopsy technologies that target the detection of cell-free DNA with fragments of circulating tumor DNA could be a game-changer in early cancer detection, but their adoption requires further clinical testing and consideration of harm. "

Cancer mRNA vaccines: clinical advances and future opportunities
(Posted May 20, 2024 10AM)

From the abstract: "Thus far, no mRNA-based cancer vaccines have received regulatory approval, although several phase I–II trials have yielded promising results, including in historically poorly immunogenic tumours. Furthermore, many early phase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations and iterations that might optimize the activity of these agents. "

Genomic sequencing research in pediatric cancer care: Decision-making, attitudes, and perceived utility among adolescents and young adults and their parents
(Posted May 18, 2024 4PM)

From the abstract: "Professional guidelines recommend engaging adolescents and young adults (AYAs) in medical decision-making (DM), including whether to undergo genomic sequencing (GS). We explored DM around GS and attitudes after return of GS results among a diverse group of AYAs with cancer and their parents. Methods: We surveyed AYAs with cancer (n=75) and their parents (n=52) six months after receiving GS results through the Texas KidsCanSeq Study. We analyzed AYAs’ DM role in GS research enrollment and their satisfaction with that role. We compared AYAs’ and parents’ self-reported understanding of, attitudes toward, and perceived utility of the AYAs’ GS results. "


news Latest News and Publications
Actionability and familial uptake following opportunistic genomic screening in a pediatric cancer cohort. External Web Site Icon
Sophia Hammer-Hansen et al. Eur J Hum Genet 2024
Cascade genetic testing: an underutilized pathway to equitable cancer care? External Web Site Icon
Roni Nitecki Wilke et al. Fam Cancer 2024
Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study. External Web Site Icon
Saskia Schlootz et al. Swiss Med Wkly 2024 1543386
Genomic sequencing research in pediatric cancer care: Decision-making, attitudes, and perceived utility among adolescents and young adults and their parents. External Web Site Icon
Amanda M Gutierrez et al. Genet Med 2024 101168
Inappropriate Ordering of Multitarget Stool DNA Tests for Colon Cancer Screening. External Web Site Icon
Aaron B Ahn et al. J Am Board Fam Med 2024 37(2) 328-331
Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches. External Web Site Icon
Ray Manneh et al. JCO Precis Oncol 2024 8e2300628
Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer. External Web Site Icon
Jeanna Wallenta Law et al. JCO Precis Oncol 2024 8e2400075
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer. External Web Site Icon
Umberto Malapelle et al. Br J Cancer 2024
Risk Factors and Mortality Among Women With Interval Breast Cancer vs Screen-Detected Breast Cancer. External Web Site Icon
Huiyeon Song et al. JAMA Netw Open 2024 7(5) e2411927
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. External Web Site Icon
Nadine Tung et al. J Clin Oncol 2024 JCO2400662

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP